跳至主要内容
临床试验/NCT03956433
NCT03956433已完成不适用

Investigation of the Effect of Daily Consumption of Bioactive Enriched Foods (BEFs) on Biochemical and Anthropometric Markers of the Metabolic Syndrome in Human Volunteers (a Pilot Study)

University of Leeds2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2014年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
35
试验地点
2
主要终点
Fasting HDL concentration

研究概览

简要总结

This pilot study will investigate the enrichment type, in pancakes, most effective at improving markers of metabolic syndrome. Ready-made pancakes enriched with either docosahexaenoic acid (DHA), beta-glucan (BG) or anthocyanins (AC), alone or in combination of DHA+BG or DHA+AC, will be consumed for 4 weeks.

详细描述

There is scientific evidence to support health claims that docosahexaenoic acid (DHA), an omega-3 fatty acid, and beta-glucan (BG), a soluble plant fibre, can help to maintain healthy cholesterol and triglyceride levels. It is also reported that anthocyanins (AC), colour pigments found in many dietary plants, can lower concentrations of low-density lipoprotein (LDL) cholesterol and increase high-density lipoprotein (HDL) cholesterol in dyslipidemic adults. Research studies often focus on bioactives administered as supplements, this study will also investigate the effectiveness of the food matrix. The project addresses the exploitation of bioactive compounds extracted from natural food sources that when added as ingredients to foods and consumed within the common diet, could significantly benefit human health and wellbeing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

盲法说明

Double-blind

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects will be eligible to the pilot study if they present with two to four of the criteria for metabolic syndrome (MetS), at least one of them being alteration of fasting triglycerides or HDL-C cholesterol. MetS is defined when three of the following criteria are met:
  • elevated waist circumference (men ≥ 102 cm; women ≥ 88 cm)
  • elevated fasting triglycerides (≥ 150 mg/dL)
  • reduced fasting HDL-cholesterol (men ≤ 40 mg/dL; women ≤ 50 mg/dL)
  • elevated blood pressure (systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg) or hypotensive treatment
  • elevated fasting glucose (≥ 110 mg/dL)

排除标准

  • Participants are excluded if three or more clinical criteria for metabolic syndrome are met. Additionally, major exclusion criteria are:
  • regular drug therapy with impact on serum lipids;
  • diabetes (fasting glucose > 1.26 g/L, or anti-diabetic treatment);
  • recent history of cancer or cancer treatment (less than 2 years);
  • active or recently diagnosed intestinal malabsorption or disorders associated with malabsorption: Crohn's disease, short bowel syndrome, Pancreatic insufficiency , cystic fibrosis, Tropical Sprue, whipple's disease, chronic pancreatitis, gastrojejunostomy, surgical treatments for obesity, cholestasis, biliary atresia, parasite infections, HIV/AIDS
  • familial dyslipidemia;
  • use of medication known to cause malabsorption: tetracycline, cholestyramine, thiazide diuretics, aluminum/magnesium hydroxide, colchicine, neomycin, methotrexate, methyldopa, and allopurinol, and laxatives
  • illegal drug use, chronic alcoholism or active smoking;
  • intensive physical exercise (≥ 5 hour/week);
  • consumption of nutritional supplements containing DHA, BG or AC;
  • history of allergy or intolerance to any components used in BEFs, celiac disease, lactose intolerance, allergy to milk or egg proteins;
  • institutionalised patients, those who lack autonomy to consent or are unable to meet all examinations;
  • women who are pregnant, lactating or actively trying to conceive;
  • participation in other clinical trials that may impact on outcome;
  • subjects deprived of their liberty by judicial or administrative decision.

结局指标

主要结局

Fasting HDL concentration

时间窗: Day 1 to Day 28

Change in fasting HDL concentration between baseline and endpoint

Fasting triglyceride concentration

时间窗: Day 1 to Day 28

Change in fasting triglyceride concentration between baseline and endpoint

次要结局

  • Waist circumference(Day 1 to day 28)
  • Blood pressure(Day 1 to day 28)
  • Fasting blood glucose concentration(Day 1 to day 28)
  • Body mass index(Day 1 to day 28)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Samantha Sutulic

Postdoctoral Research Fellow

University of Leeds

研究点 (2)

Loading locations...

相似试验

Effect of Bioactive Enriched Food on Markers of... | 临床试验